Overview

The Gene Technology Amendment (Cauldron Molecules Pty Ltd—Borenore) Rules 2023, enacted by the Australian Government, provides for a trial to optimise the fermentation and processing of recombinant proteins using genetically modified yeast in Borenore, New South Wales. This trial seeks to address the gap in sustainable protein production technologies by utilising genetically modified Pichia pastoris yeast to produce recombinant animal proteins such as bovine milk, chicken egg, and silk fibre from a non-animal source. The Office of the Gene Technology Regulator is responsible for assessing the application and has prepared a Risk Assessment and Risk Management Plan (RARMP) to evaluate the potential risks to human health and safety and the environment. The Regulator is inviting written submissions from the public to contribute to the decision-making process before issuing a licence to Cauldron Molecules Pty Ltd. Submissions should reference DIR 200 and be submitted by 22 December 2023. The policy objective of this legislation is to facilitate the development of sustainable and innovative protein production technologies while ensuring adequate protection of human health and safety and the environment.

Scope and Application

The invitation to comment on the trial of fermentation and processing of recombinant proteins using genetically modified yeast by Cauldron Molecules Pty Ltd pertains to a specific application within the scope of the Gene Technology Act 2000 (Cth). This legislation applies to Cauldron Molecules Pty Ltd, a company seeking to optimise fermentation processes and characterise genetically modified (GM) yeast for the production of recombinant proteins from non-animal sources at their facility in Borenore, New South Wales. The Act regulates the use of genetically modified organisms (GMOs) and their products, ensuring that such activities are conducted with adequate safeguards to protect human health and the environment. The trial involves the use of GM yeast (Pichia pastoris) for producing recombinant animal proteins, which will not be used for human food but may be inactivated for use in animal feed or as a soil conditioner. The geographic reach of this legislation is national, as it falls under the Commonwealth's purview to regulate gene technology activities that could potentially pose risks to human health and the environment. Any exclusions or exemptions are not explicitly stated in this notice, but the submission of a Risk Assessment and Risk Management Plan (RARMP) as part of the application process indicates a thorough evaluation of potential risks. The application's assessment and subsequent decision by the Gene Technology Regulator may be influenced by subordinate instruments that provide further detail on regulatory requirements and risk management strategies.

Key Provisions

The legislation in question, C2023G01189, pertains to the assessment of an application by Cauldron Molecules Pty Ltd to conduct a trial of fermentation and processing of recombinant proteins using genetically modified yeast. The application focuses on optimising the fermentation process and characterising genetically modified (GM) yeast, specifically Pichia pastoris, which is used to produce recombinant animal proteins such as bovine milk, chicken egg, and silk fibre from a non-animal source (section 1). The trial is proposed to occur at a facility located in Borenore, Cabonne Shire Council, New South Wales over a period of five years. Notably, the GM yeast cultivated in this process will not be used for human food consumption, and only inactivated yeast may be used in animal feed preparations or as a soil conditioner (section 2). The Gene Technology Regulator has developed a Risk Assessment and Risk Management Plan (RARMP) to evaluate this application comprehensively. The Regulator is soliciting written submissions from the public to ensure that the proposed activities align with the protection of human health and safety and environmental preservation. This consultation process is integral to the decision-making framework before any licence is issued. The RARMP and relevant information can be accessed through the Regulator's website (search for DIR 200) or by contacting the specified office. Submissions must reference DIR 200 and be submitted by 22 December 2023 to be considered (section 3). The obligations imposed by the Act on Cauldron Molecules Pty Ltd and other relevant parties include the submission of a thorough Risk Assessment and Risk Management Plan. This document must detail the potential risks associated with the fermentation and processing of recombinant proteins using GM yeast and propose measures to mitigate these risks. Furthermore, the entity must ensure that the proposed GM yeast and resultant recombinant proteins do not pose any threat to human health or the environment. Compliance with these obligations is crucial for the Regulator to assess the application effectively (section 4). Any breaches of the Act may lead to civil or criminal consequences. While specific offences and penalties are not detailed in the legislation, the overarching legal framework governing gene technology in Australia imposes stringent penalties for non-compliance. These can include substantial fines and, in severe cases, imprisonment. The Regulator is tasked with enforcing these penalties to ensure adherence to the Act's provisions, thereby safeguarding human health and the environment (section 5).